Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures

Tumor Biology

Volumn 37, Issue 10, 2016, Pages 12941-12957

  Golubnitschaja, Olga ^a   Debald, Manuel ^a   Yeghiazaryan, Kristina ^a   Kuhn, Walther ^a   Pešta, Martin ^b   Costigliola, Vincenzo ^c   Grech, Godfrey ^d  

^a UNIVERSITY OF BONN   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c European Medical Association   (Belgium)

^d UNIVERSITY OF MALTA   (Malta)

Author keywords

Breast cancer; Epidemic; Individualised patient profile; Predictive preventive personalised medicine; Questionnaire

Indexed keywords

BREAST CANCER; BREAST FEEDING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; DIET; ECOTOXICITY; ENVIRONMENTAL FACTOR; EPIDEMIC; FOOD QUALITY; HUMAN; MATERNAL AGE; MENARCHE; MENOPAUSE; OCCUPATIONAL EXPOSURE; POLLUTION; PRACTICE GUIDELINE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHIFT WORKER; SOCIOECONOMICS; BREAST NEOPLASMS; FEMALE; PREGNANCY;

BREAST NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HUMANS; PREGNANCY; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84979519415     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5168-x     Document Type: Review

References (189)

1. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013;4(1):6.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
3. Leung GM, Thach TQ, Lam T-H, Hedley AJ, Foo W, Fielding R, et al. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer. 2002;87(9):982–8.
4. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34(2):405–12.
5. Jung YS, Na KY, Kim KS, Ahn S-H, Lee SJ, Lee S-J, et al. Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program. J Breast Cancer. 2011;14(3):229–36.
6. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):446.
7. Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Pers Med. 2016; in press.
8. Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘horizon 2020’. EPMA J. 2014;5(1):8.
9. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomark Prev. 1995;4(5):567–71.
10. Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013;105(20):1571–8.
11. Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, et al. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. Breast Cancer Res Treat. 2013;142(3):569–78.
12. Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol. 2014;143:207–22.
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187–95.
14. Ballard-Barbash R, Hunsberger S, Alciati MH, Blair SN, Goodwin PJ, McTiernan A, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9):630–43.
15. Bernstein L. Exercise and breast cancer prevention. Curr Oncol Rep. 2009;11(6):490–6.
16. Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, et al. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Res Treat. 2012;133(1):127–35.
17. Rubinstein WS, O’neill SM, Rothrock N, Starzyk EJ, Beaumont JL, Acheson LS, et al. Components of family history associated with women’s disease perceptions for cancer: a report from the Family Healthware™ Impact Trial. Genitourin Med. 2011;13(1):52–62.
18. Randall TC, Armstrong K. Health care disparities in hereditary ovarian cancer: are we reaching the underserved population? Curr Treat Options in Oncol. 2016;17(8):39.
19. Alford SH, Leadbetter S, Rodriguez JL, Hawkins NA, Scholl LE, Peipins LA. Cancer screening among a population-based sample of insured women. Prev Med Rep. 2015;2:15–20.
20. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.
21. Heikkilä K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, et al. Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women. BMJ. 2013;346:f165.
22. Fazzo L, Carere M, Tisano F, Bruno C, Cernigliaro A, Cicero MR, et al. Cancer incidence in Priolo, Sicily: a spatial approach for estimation of industrial air pollution impact. Geospat Health. 2016;11(1):320.
23. Zimeri AM, Robb SW, Hassan SM, Hire RR, Davis MB. Assessing heavy metal and PCB exposure from tap water by measuring levels in plasma from sporadic breast cancer patients, a pilot study. Int J Environ Res Public Health. 2015;12(12):15683–91.
24. Alatise OI, Schrauzer GN. Lead exposure: a contributing cause of the current breast cancer epidemic in Nigerian women. Biol Trace Elem Res. 2010;136(2):127–39.
25. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.
26. Little MP, McElvenny DM. Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors—differences in excess relative and absolute risk from female breast cancer. Environ Health Perspect. 2016. doi:10.1289/EHP151.
27. White AJ, Bradshaw PT, Herring AH, Teitelbaum SL, Beyea J, Stellman SD, et al. Exposure to multiple sources of polycyclic aromatic hydrocarbons and breast cancer incidence. Environ Int. 2016;89–90:185–92.
28. Williams DR, Mohammed SA, Shields AE. Understanding and effectively addressing breast cancer in African American women: unpacking the social context. Cancer. 2016. doi:10.1002/cncr.29935.
29. Kotepui M. Diet and risk of breast cancer. Contemp Oncol Pozn Pol. 2016;20(1):13–9.
30. Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol. 2012;47(3):204–12.
31. Cebioglu M, Schild H, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 2010;1(1):130–7.
32. Zambacos GJ, Molnar C, Mandrekas AD. Silicone lymphadenopathy after breast augmentation: case reports, review of the literature, and current thoughts. Aesthet Plast Surg. 2013;37(2):278–89.
33. Ozkaya N, Grogg KL, Dogan A. Seroma-associated anaplastic large cell lymphoma arising in the background of subcutaneous calcinosis: beyond breast implants. Histopathology. 2016. doi:10.1111/his.13012.
34. Favia G, Tempesta A, Limongelli L, Crincoli V, Piattelli A, Maiorano E. Metastatic breast cancer in medication-related osteonecrosis around mandibular implants. Am J Case Rep. 2015;16:621–6.
35. Bhandari S, Rattan V, Panda N, Vaiphei K, Mittal BR. Oral cancer or periimplantitis: a clinical dilemma. J Prosthet Dent. 2016;115(6):658–61.
36. Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast cancer susceptibility in rotating shift workers. Int J Cancer. 2012;131(11):2547–52.
37. Rafnsson V, Tulinius H, Jónasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001;12(2):95–101.
38. Schubauer-Berigan MK, Anderson JL, Hein MJ, Little MP, Sigurdson AJ, Pinkerton LE. Breast cancer incidence in a cohort of U.S. flight attendants. Am J Ind Med. 2015;58(3):252–66.
39. Pudrovska T, Carr D, McFarland M, Collins C. Higher-status occupations and breast cancer: a life-course stress approach. Soc Sci Med 1982. 2013;89:53–61.
40. Härmä M, Kecklund G. Shift work and health—how to proceed? Scand J Work Environ Health. 2010;36(2):81–4.
41. Wang X-S, Armstrong MEG, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond). 2011;61(2):78–89.
42. Richter K, Acker J, Kamcev N, Bajraktarov S, Piehl A, Niklewski G. Recommendations for the prevention of breast cancer in shift workers. EPMA J. 2011;2(4):351–6.
43. Costa G, Haus E, Stevens R. Shift work and cancer—considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010;36(2):163–79.
44. Pijpe A, Slottje P, van Pelt C, Stehmann F, Kromhout H, van Leeuwen FE, et al. The Nightingale study: rationale, study design and baseline characteristics of a prospective cohort study on shift work and breast cancer risk among nurses. BMC Cancer. 2014;14:47.
45. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. J Natl Cancer Inst. 2001;93(20):1563–8.
46. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41(13):2023–32.
47. Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 2006;17(4):531–7.
48. Fritschi L, Glass DC, Heyworth JS, Aronson K, Girschik J, Boyle T, et al. Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses. 2011;77(3):430–6.
49. Linnersjö A, Hammar N, Dammström B-G, Johansson M, Eliasch H. Cancer incidence in airline cabin crew: experience from Sweden. Occup Environ Med. 2003;60(11):810–4.
50. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–53.
51. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer. 2002;38(1):27–43.
52. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Nat Cancer Ins Monogr. 2004;(32):40–50.
53. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609.
54. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
55. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25.
56. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887–99.
57. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–30.
58. Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 2005;65(20):9595–600.
59. Girschik J, Heyworth J, Fritschi L. Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case-control study. Am J Epidemiol. 2013;177(4):316–27.
60. Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, et al. Association between sleep and breast cancer incidence among postmenopausal women in the Women’s Health Initiative. Sleep. 2013;36(10):1437–44.
61. Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and quality of life in breast cancer patients. J Pain Symptom Manag. 2002;24(5):471–80.
62. Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer. 2006;14(3):201–9.
63. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26(5):768–77.
64. Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–10.
65. Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, et al. Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J. 2016;7(Suppl 1):A25.
66. Vanharanta S. A hypoxic ticket to the bone metastatic niche. Breast Cancer Res. 2015;17:122.
67. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5(1):11.
68. Flammer syndrome. Available from: http://www.flammer-syndrome.ch/index.php?id=33. Accessed 26 Jan 2016
69. Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J. 2010;1(2):263–72.
70. Golubnitschaja O, Yeghiazaryan K, Flammer J. Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J. 2010;1(2):237–44.
71. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–67.
72. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–25.
73. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff Proj Hope. 2009;28(5):w822–31.
74. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J Cancer. 2009;124(3):698–712.
75. Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14.
76. Hilakivi-Clarke L, Forsén T, Eriksson JG, Luoto R, Tuomilehto J, Osmond C, et al. Tallness and overweight during childhood have opposing effects on breast cancer risk. Br J Cancer. 2001;85(11):1680–4.
77. Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 2010;171(11):1183–94.
78. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status—the Japan public health center-based prospective study. Int J Cancer. 2011;129(5):1214–24.
79. Robinson WR, Tse CK, Olshan AF, Troester MA. Body size across the life course and risk of premenopausal and postmenopausal breast cancer in black women, the Carolina Breast Cancer Study, 1993-2001. Cancer Causes Control. 2014;25(9):1101–17.
80. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114–36.
81. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: is predictive diagnosis possible? In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality? New York: Nova Science Publishers Inc; 2009. p. 247–62.
82. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608–17.
83. Wu AH, Kurian AW, Kwan ML, John EM, Lu Y, Keegan THM, et al. Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol Biomark Prev. 2015;24(2):361–8.
84. Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015;19(2):48–79.
85. Pronk NP, Anderson LH, Crain AL, Martinson BC, O’Connor PJ, Sherwood NE, et al. Meeting recommendations for multiple healthy lifestyle factors. Prevalence, clustering, and predictors among adolescent, adult, and senior health plan members. Am J Prev Med. 2004;27(2 Suppl):25–33.
86. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384–98.
87. Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008;10(2):R26.
88. Janz KF, Dawson JD, Mahoney LT. Tracking physical fitness and physical activity from childhood to adolescence: the muscatine study. Med Sci Sports Exerc. 2000;32(7):1250–7.
89. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens. 1995;8(7):657–65.
90. Guo SS, Huang C, Maynard LM, Demerath E, Towne B, Chumlea WC, et al. Body mass index during childhood, adolescence and young adulthood in relation to adult overweight and adiposity: the Fels Longitudinal Study. Int J Obes Relat Metab Disord. 2000;24(12):1628–35.
91. Nicklas TA, von Duvillard SP, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to dyslipidemia in adults: the Bogalusa Heart Study. Int J Sports Med. 2002;23(Suppl 1):S39–43.
92. Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. The role of the cardiovascular specialist. Can J Cardiol. 1999;15(Suppl G):1G–119G.
93. Raitakari OT, Porkka KV, Räsänen L, Viikari JS. Relations of life-style with lipids, blood pressure and insulin in adolescents and young adults. The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 1994;111(2):237–46.
94. Bergström E, Hernell O, Persson LA. Cardiovascular risk indicators cluster in girls from families of low socio-economic status. Acta Paediatr Oslo Nor 1992. 1996;85(9):1083–90.
95. Pate RR, Heath GW, Dowda M, Trost SG. Associations between physical activity and other health behaviors in a representative sample of US adolescents. Am J Public Health. 1996;86(11):1577–81.
96. McKenna M, Taylor W, Marks J, Koplan J. Current issues and challenges in chronic disease control. In: Brownson R, Remington P, Davis J, editors. Chronic disease epidemiology and control. Washington DC: United Book; 1998.
97. Golubnitschaja O. Changing long-held beliefs is never easy: a proposal for multimodal approaches in female healthcare—an integrative view. In: Costigliola V, editor. Healthcare overview: new perspectives. vol. 1. Dordrecht: Springer; 2012. p. 251–68.
98. Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Adv Nutr. 2012;3(6):755–62.
99. Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, et al. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res. 2006;26(3B):2345–8.
100. Plazar N, Jurdana M. Hyperhomocysteinemia and the role of B vitamins in cancer. Radiol Oncol. 2010;44(2):79–85.
101. Keshteli AH, Baracos VE, Madsen KL. Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review. World J Gastroenterol. 2015;21(4):1081–90.
102. Essouma M, Noubiap JJN. Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res. 2015;3:24.
103. Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N. Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience. 2013;252:302–19.
104. Yun J, Johnson JL, Hanigan CL, Locasale JW. Interactions between epigenetics and metabolism in cancers. Front Oncol. 2012;2:163.
105. Kedzierska M, Malinowska J, Glowacki R, Olas B, Bald E, Jeziorski A, et al. The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. Mol Cell Biochem. 2011;355(1–2):193–9.
106. Lin J, Lee I-M, Song Y, Cook NR, Selhub J, Manson JE, et al. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res. 2010;70(6):2397–405.
107. Wu X, Zou T, Cao N, Ni J, Xu W, Zhou T, et al. Plasma homocysteine levels and genetic polymorphisms in folate metablism are associated with breast cancer risk in Chinese women. Hered Cancer Clin Pract. 2014;12(1):2.
108. Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165(12):1543–50.
109. Cho HJ, Lavretsky H, Olmstead R, Levin M, Oxman MN, Irwin MR. Prior depression history and deterioration of physical health in community-dwelling older adults—a prospective cohort study. Am J Geriatr Psychiatry. 2010;18(5):442–51.
110. Monroe SM, Harkness KL. Life stress, the ‘kindling’ hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev. 2005;112(2):417–45.
111. Jim HSL, Small BJ, Minton S, Andrykowski M, Jacobsen PB. History of major depressive disorder prospectively predicts worse quality of life in women with breast cancer. Ann Behav Med. 2012;43(3):402–8.
112. Irwin MR, Olmstead RE, Ganz PA, Haque R. Sleep disturbance, inflammation and depression risk in cancer survivors. Brain Behav Immun. 2013;30(Suppl):S58–67.
113. Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, et al. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006;68(5):675–83.
114. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252–7.
115. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsych. 2003;8(4):229–40.
116. Berkey CS, Willett WC, Frazier AL, Rosner B, Tamimi RM, Rockett HRH, et al. Prospective study of adolescent alcohol consumption and risk of benign breast disease in young women. Pediatrics. 2010;125(5):e1081–7.
117. Berkey CS, Tamimi RM, Rosner B, Frazier AL, Colditz GA. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer. 2012;118(11):2796–803.
118. Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, Boeing H, et al. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. BMJ Open. 2014;4(7):e005245.
119. Mathes RW, Malone KE, Daling JR, Davis S, Lucas SM, Porter PL, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomark Prev. 2008;17(11):3116–22.
120. Li CI, Mathes RW, Malone KE, Daling JR, Bernstein L, Marchbanks PA, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomark Prev. 2009;18(7):2030–4.
121. Li CI, Mathes RW, Bluhm EC, Caan B, Cavanagh MF, Chlebowski RT, et al. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 2010;28(6):1005–10.
122. Winter AC, Rexrode KM, Lee I-M, Buring JE, Tamimi RM, Kurth T. Migraine and subsequent risk of breast cancer: a prospective cohort study. Cancer Causes Control. 2013;24(1):81–9.
123. Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interf Cytokine Res. 2015;35(1):1–16.
124. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159–69.
125. Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev. 2012;31(1–2):247–68.
126. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.
127. Dupont WD, DL P. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.
128. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353(3):275–85.
129. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71(4):1258–65.
130. Collins LC, Achacoso NA, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP, et al. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007;20(11):1149–55.
131. Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat. 2014;145(3):567–79.
132. Liu Y, Tamimi RM, Berkey CS, Willett WC, Collins LC, Schnitt SJ, et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 2012;129(5):e1192–8.
133. Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, et al. Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomark Prev. 2005;14(12):2889–97.
134. Beaber EF, Malone KE, Tang M-TC, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomark Prev. 2014;23(5):755–64.
135. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011;18(4):385–92.
136. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol. 2011;8(11):669–76.
137. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012;104(7):517–27.
138. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128(1):144–56.
139. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933–41.
140. Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, et al. Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. Endocr Relat Cancer. 2013;20(6):875–87.
141. Berrington de González A. Estimates of the potential risk of radiation-related cancer from screening in the UK. J Med Screen. 2011;18(4):163–4.
142. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727–37.W237-242
143. Zhang XH-F, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19(23):6389–97.
144. Debald M, Yeghiazaryan K, Cebioglu M, Kuhn W, Schild HH, Golubnitschaja O. ‘Suspect molecular signature’ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J. 2013;4(1):22.
145. Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: quo vadis? World J Clin Oncol. 2014;5(2):71–81.
146. Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.
147. Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, Shien T, et al. DNA methylation status of REIC/Dkk-3 gene in human malignancies. J Cancer Res Clin Oncol. 2012;138(5):799–809.
148. Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat. 2010;122(3):699–710.
149. Stötzer OJ, Lehner J, Fersching-Gierlich D, Nagel D, Holdenrieder S. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumour Biol. 2014;35(2):1183–91.
150. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006;119(6):1403–11.
151. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 2006;233(1):98–107.
152. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013;8(5):e63165.
153. Slattery ML, John EM, Stern MC, Herrick J, Lundgreen A, Giuliano AR, et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013;140(3):587–601.
154. Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Lewinger JP, Stern MC, et al. Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study. Int J Cancer. 2014;134(3):629–44.
155. Resler AJ, Malone KE, Johnson LG, Malkki M, Petersdorf EW, McKnight B, et al. Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer. 2013;13:219.
156. Melander O, Belting M, Manjer J, Maisel AS, Hedblad B, Engström G, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomark Prev. 2014;23(8):1672–6.
157. Baer HJ, Brawarsky P, Murray MF, Haas JS. Familial risk of cancer and knowledge and use of genetic testing. J Gen Intern Med. 2010;25(7):717–24.
158. Warren Andersen S, Trentham-Dietz A, Gangnon RE, Hampton JM, Figueroa JD, Skinner HG, et al. Reproductive windows, genetic loci, and breast cancer risk. Ann Epidemiol. 2014;24(5):376–82.
159. Elebro K, Butt S, Dorkhan M, Jernström H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes Control. 2014;25(8):945–57.
160. Chakravarthi BVSK, Varambally S. Targeting the link between late pregnancy and breast cancer. eLife. 2013;2:e01926.
161. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25(5):368–87.
162. Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast. 2013;22(Suppl 2):S30–7.
163. Steindorf K, Schmidt M, Ulrich C. Effects of physical activity on cancer risk and disease progression after cancer diagnosis. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2012;55(1):10–6.
164. Graf C, Wessely N. Physical activity in the prevention and therapy of breast cancer. Breast Care. 2010;5(6):389–94.
165. Orlando LA, RR W, Beadles C, Himmel T, Buchanan AH, Powell KP, et al. Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. Am J Med Genet C: Semin Med Genet. 2014;166C(1):24–33.
166. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette smoking and the incidence of breast cancer. Arch Intern Med. 2011;171(2):125–33.
167. Long-term smoking increases breast cancer risk. http://www.breastcancer.org/research-news/20110124. Accessed 18 Jan 2016
168. Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control. 2011;20(1):e2.
169. Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, et al. Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocr Relat Cancer. 2014;21(4):629–38.
170. Bracci M, Manzella N, Copertaro A, Staffolani S, Strafella E, Barbaresi M, et al. Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-β-estradiol levels. Scand J Work Environ Health. 2014;40(3):295–304.
171. Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y. Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer. 2013;13:498.
172. Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342(1):9–18.
173. Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer. 2012;118(23):5929–36.
174. Girschik J, Fritschi L, Erren TC, Heyworth J. Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk. Cancer Causes Control. 2013;24(5):919–28.
175. Malina C, Frigo S, Mathelin C. Sleep and breast cancer: is there a link? Gynécologie Obstétrique Fertil. 2013;41(2):105–9.
176. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev. 2009;18(1):74–9.
177. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomark Prev. 2010;19(3):729–37.
178. Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev. 2013;14(8):665–78.
179. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.
180. Gallagher EJ, LeRoith D. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes. 2013;20(5):485–94.
181. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer. 2014;23(2):134–40.
182. Xu C-X, Zhu H-H, Zhu Y-M. Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J Diabetes. 2014;5(3):372–80.
183. Naushad SM, Reddy CA, Kumaraswami K, Divyya S, Kotamraju S, Gottumukkala SR, et al. Impact of hyperhomocysteinemia on breast cancer initiation and progression: epigenetic perspective. Cell Biochem Biophys. 2014;68(2):397–406.
184. Hansen MV, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, et al. The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open. 2012;2(1):e000647.
185. Hrushesky WJM, Grutsch J, Wood P, Yang X, E-Y O, Ansell C, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009;8(4):387–97.
186. Lemogne C, Consoli SM, Melchior M, Nabi H, Coeuret-Pellicer M, Limosin F, et al. Depression and the risk of cancer: a 15-year follow-up study of the GAZEL cohort. Am J Epidemiol. 2013;178(12):1712–20.
187. Nakaya N. Effect of psychosocial factors on cancer risk and survival. J Epidemiol Jpn Epidemiol Assoc. 2014;24(1):1–6.
188. M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33–47.
189. Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives—the Norwegian Women and Cancer study. Int J Cancer. 2007;121(3):645–8.